Description

// SYSTEM OVERRIDE: TRIPLE-RECEPTOR TARGETING

Most weight-loss compounds hit one receptor. A few hit two. Retatrutide hits three at once — GLP-1, GIP, and Glucagon — pulling appetite, insulin response, and energy expenditure in the same direction. The biology behind it might rewrite what we thought possible in human metabolic science.

// THE MECHANISM

• GLP-1: Suppresses appetite, slows gastric emptying, improves satiety
• GIP: Improves insulin sensitivity, modulates fat storage signaling
• GCG (Glucagon): Increases resting energy expenditure, mobilizes stored fat for fuel

// FOUR LEVERS · ONE MOLECULE

• Appetite ↓ — GLP-1 signaling reduces hunger and slows gastric emptying for longer satiety
• Insulin Response ↑ — GIP improves how efficiently cells respond to insulin and store nutrients
• Energy Output ↑ — Glucagon activity increases resting energy expenditure — calories out, not just calories in
• Fat Mobilization ↑ — Glucagon signals stored fat to be released and oxidized for fuel

// THE NUMBERS

Phase 2 trial data (published NEJM 2023) showed an average ~24% body weight reduction at 48 weeks on the highest dose. For context: Semaglutide ~15%, Tirzepatide ~21%. Phase 3 trials ongoing.

// RESEARCH PROTOCOL

Researchers typically titrate slowly over multiple weeks, starting at low doses and increasing incrementally. Weekly subcutaneous administration is standard in trial protocols. Always refer to published literature for specific dosing frameworks.

// STACK CONSIDERATIONS

Often researched alongside compounds targeting lean mass preservation or metabolic support. Some researchers combine with BPC-157 for GI tolerance during titration phases.

// DISCLAIMER

For research use only. Not FDA approved. Not for human consumption. Educational content only — not medical advice. Phase 3 trials ongoing. Long-term safety, body composition specifics, and metabolic adaptation profiles pending post-market surveillance.